Cutler Group’s Clearside Biomedical CLSD Stock Holding History

Cutler Group’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-300	Closed	-$3K	–	5767
2021 Q2	$3K	Buy	+300	New	+$13.9K	﹤0.01%	4735
2018 Q3	–	Sell	-520	Closed	-$15K	–	4145
2018 Q2	$15K	Buy	+520	New	+$87.7K	﹤0.01%	2369

Other funds holding CLSD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cutler Group's CLSD Position: Q1 2024 in Review

Cutler Group sold out of Clearside Biomedical (CLSD) in Q1 2024, closing a stake of 133 shares — an estimated $2K sold.

Cutler Group first reported a position in CLSD in Q1 2018 and held it in 20 quarters. The position peaked at $69K in Q2 2018. 51 funds tracked by Wall St. Rank hold CLSD as of Q1 2024.

Cutler Group reported no remaining Clearside Biomedical position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 133 Clearside Biomedical shares in Q1 2024, an estimated $2K.
Cutler Group first reported a position in Clearside Biomedical in Q1 2018 and held it in 20 quarters.
Cutler Group's Clearside Biomedical position peaked at $69K in Q2 2018.
51 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.